Triacetin

Triacetin (Glyceryl triacetate) is a synthetic compound that is a triester of glycerol and acetic acid, orally active. Triacetin increases acetate bioavailability in glioma cells. Triacetin induces glioma cell growth arrest and Apoptosis. Triacetin freely crosses the blood brain barrier/plasma membrane. Triacetin increases histone acetylation and enhances Temozolomide (HY-17364) (TMZ) chemotherapeutic efficacy ^[1][2]. In Vitro: Triacetin (0.25%, 24 h) induces growth arrest of HOG, Hs683, U87, U251, OG33, OG35 GBM9, GBM12, GBM34, GBM2, GBM8 and GBM44 cells in vitro^[1].
Triacetin (25 mM, 24 h) causes effective inhibition on the U87MG (human malignant glioma) cell viability^[2].
Triacetin (12.5-25 mM, 24 h) induces clear G2/M cell-cycle arrest in U87MG cells.^[2].
Triacetin (12.5 mM) induces apoptosis in GBM cancer cells^[2].
Triacetin (25 mM, 24 h) decreases the class I and class II HDAC (histone deacetylase) mRNA expression in U87MG cells^[2].
Triacetin (12.5 mM, 24 h) inhibits HDAC-8 activity in U87MG cells^[2].
Triacetin (12.5 mM, 24 h) activates the mTOR complexes downstream genes which play an important role in cancer cell metabolism such as S6K1, mSIN1, Protor 2, and PKCα^[2].
Triacetin (12.5 mM, 24 h) shows an increased tumor suppressor miRs that can inhibit growth, proliferation, invasion, migration, and angiogenesis in U87MG cells^[2].
In Vivo: Triacetin (5.0 g/kg with 10% v/v oral-sweet SF, p.o., daily, 14 days) enhances TMZ (Temozolomide) (HY-17364) chemotherapeutic efficacy in mice engrafted with oligodendroglioma-derived GSCs^[1].
Triacetin (5.0 g/kg with 10% v/v Ora-Sweet SF, p.o., daily, 40days) alone increases survival of mice orthotopically engrafted with GBM-derived GSCs^[1].